MedTrace Logo

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

NCT00957996 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2015-02-12

Study results available
· View outcomes & findings →

Summary

This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.

Conditions

Interventions

DRUG

Peramivir

300 mg twice daily

DRUG

Peramivir

600 mg once daily

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-10-31
Completion
2011-08-31

Countries

  • United States
  • Australia
  • Canada
  • Mexico
  • New Zealand
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00957996 on ClinicalTrials.gov